Macrophages predict treatment outcome in Hodgkin's lymphoma

Haematologica

Volumn 96, Issue 2, 2011, Pages 186-189

  Steidl, Christian ^a   Farinha, Pedro ^a   Gascoyne, Randy D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD163 ANTIGEN; CD68 ANTIGEN; PEANUT AGGLUTININ;

AGE DISTRIBUTION; CLASSICAL HODGKIN LYMPHOMA; COMPUTER ASSISTED DIAGNOSIS; EDITORIAL; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION PROFILING; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; LATENT PERIOD; MACROPHAGE; PHENOTYPE; PROGNOSIS; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; MACROPHAGES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79551642617     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.033316     Document Type: Editorial

References (36)

1. Bjorkholm M, Axdorph U, Grimfors G, Merk K, Johansson B, Landgren O, et al. Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial. Ann Oncol. 1995;6(9):895-9.
2. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003; 21(18):3431-9.
3. Salloum E, Doria R, Schubert W, Zelterman D, Holford T, Roberts KB, et al. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol. 1996;14(9):2435-43.
4. van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18(3):487-97.
5. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339(21):1506-14.
6. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC 2008.
7. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 2009;9(1):15-27.
8. Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard J, d'Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica. 2011;96(2):269-76.
9. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumorassociated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362(10):875-85.
10. Ree HJ, Kadin ME. Macrophage-histiocytes in Hodgkin's disease. The relation of peanut-agglutinin-binding macrophage-histiocytes to clinicopathologic presentation and course of disease. Cancer. 1985; 56(2):333-8.
11. Sanchez-Aguilera A, Montalban C, de la Cueva P, Sanchez-Verde L, Morente MM, Garcia-Cosio M, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood. 2006;108(2):662-8.
12. Sanchez-Espiridion B, Montalban C, Lopez A, Menarguez J, Sabin P, Ruiz-Marcellan C, et al A molecular risk score based on four functional pathways for advanced classical Hodgkin lymphoma. Blood. 2010;116(8):e12-7.
13. Sanchez-Espiridion B, Sanchez-Aguilera A, Montalban C, Martin C, Martinez R, Gonzalez-Carrero J, et al. A TaqMan low-density array to predict outcome in advanced Hodgkin's lymphoma using paraffin-embedded samples. Clin Cancer Res. 2009;15(4):1367-75.
14. Glaser SL, Lin RJ, Stewart SL, Ambinder RF, Jarrett RF, Brousset P, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70(4):375-382.
15. Keegan TH, Glaser SL, Clarke CA, Gulley ML, Craig FE, Digiuseppe JA, et al. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J Clin Oncol. 2005;23(30): 7604-13.
16. Jarrett RF, Stark GL, White J, Angus B, Alexander FE, Krajewski AS, et al. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood. 2005;106(7): 2444-51.
17. Diepstra A, van Imhoff GW, Schaapveld M, Karim-Kos H, van den Berg A, Vellenga E, Poppema S. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. J Clin Oncol. 2009;27(23):3815-21.
18. Engel M, Essop MF, Close P, Hartley P, Pallesen G, Sinclair-Smith C. Improved prognosis of Epstein-Barr virus associated childhood Hodgkin's lymphoma: study of 47 South African cases. J Clin Pathol. 2000;53(3):182-6.
19. Kwon JM, Park YH, Kang JH, Kim K, Ko YH, Ryoo BY, et al. The effect of Epstein-Barr virus status on clinical outcome in Hodgkin's lymphoma. Ann Hematol. 2006;85(7):463-8.
20. Lau SK, Chu PG, Weiss LM. CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol. 2004;122(5):794-801.
21. Oudejans JJ, Jiwa NM, Kummer JA, Ossenkoppele GJ, van Heerde P, Baars JW, et al. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood. 1997;89(4):1376-82.
22. Ten Berge RL, Oudejans JJ, Dukers DF, Meijer JW, Ossenkoppele GJ, Meijer CJ. Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker. Leukemia. 2001;15(3):458-64.
23. Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaen J, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11(4):1467-73.
24. Kelley TW, Pohlman B, Elson P, Hsi ED. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol. 2007;128(6):958-65.
25. Greaves P, Clear AJ, Owen DA, Macdougall F, Wilson A, Lister A, et al. An immunohistochemical score based on CD68 and FOXP3 expression in the tumour microenvironment at diagnosis defines prognostic groups in both early and advanced stage classical Hodgkin lymphoma. ASH Annual Meeting Abstracts. 2010;116:750.
26. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39-51.
27. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005;106(6):2169-74.
28. Ma Y, Visser L, Roelofsen H, de Vries M, Diepstra A, van Imhoff G, et al. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood. 2008;111(4):2339-46.
29. Lamprecht B, Walter K, Kreher S, Kumar R, Hummel M, Lenze D, et al. Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med. 2010;16(5): 571-9.
30. Hsu SM, Hsu PL. The nature of Reed-Sternberg cells: phenotype, genotype, and other properties. Crit Rev Oncog. 1994;5(2-3):213-45.
31. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24):3746-52.
32. Niens M, Visser L, Nolte IM, van der Steege G, Diepstra A, Cordano P, et al. Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br J Haematol. 2008;140(5):527-36.
33. Plattel W, Van Den Berg A, Van der Graaf AM, Vos H, Visser L, Diepstra A, van Imhoff G. Mid-Treatment plasma levels of thymus activated and regulated chemokine (TARC) predict treatment outcome in classical Hodgkin lymphoma patients. ASH Annual Meeting Abstracts. 2010;116:748.
34. Deau Benedicte, Bachy E, Ribrag V, Delarue R, Rubio MT, Bosq J, et al. Macrophages and Mast Cells Infiltration Are Biomarkers of Primary Refractory Hodgkin's Lymphoma. ASH Annual Meeting Abstracts. 2010;116:3881.
35. Yoon DH, Koh YW, Kim S, Park C-S, Lee DH, Kim S-W, et al. Prognostic significance of CD68 expression for Korean patients with Hodgkin lymphoma. ASH Annual Meeting Abstracts. 2010;116: 3888.
36. Farinha P, Rodrigues S, Fernandes T, Monteiro A, Lopes da Silva R, Salvador J, Gerivaz R, Costa F, Ferreira G, Lopes C, Lacerda T, Ferreira J, Costa I, Botelho de Sousa A. Lymphoma Associated Macrophages Predict Survival in Uniformly Treated Patients with Classical Hodgkin Lymphoma. USCAP Annual Meeting Abstracts 2011 [1257].